Drugs / Carpalatine
Carpalatine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05641480 | Jun 2022 → Dec 2025 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia, subjective cognitive decline | Shaanxi Hospital of Traditional Chinese Medicine | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carpalatine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05641480 ↗ |
| Known as | carpalatine bitartrate | “Donepezil hydrochloride tablets or carpalatine bitartrate tablets” NCT05641480 ↗ |
| Known as | Carpalatine heavy tartrate | “Carpalatine heavy tartrate tablets 1.5mg, 1 tablet/time 2 weeks before treatment, twice a day, breakfast and dinner with food, swallow.” NCT05641480 ↗ |